Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Arm, Multicenter Study to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis

Next Previous
X
Search
Trial Profile

An Open-Label, Single-Arm, Multicenter Study to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms SKIPPER
  • Sponsors Roche

    • Most Recent Events

    • 01 Jun 2023 Primary endpoint has been met. (Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient), as per Results published in the American Journal of Kidney Diseases
    • 01 Jun 2023 Results published in the American Journal of Kidney Diseases
    • 16 Dec 2021 This trial is completed in Poland according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top